Enzalutamide plus androgen-deprivation therapy (ADT) improved 5-yr overall survival significantly in patients with metastatic hormone-sensitive prostate cancer, with a 30% reduced risk of death versus placebo plus ADT. Survival benefits of enzalutamide were consistent across subgroups, including a notable 36-mo gain in patients with high-volume disease.
Enzalutamide plus androgen-deprivation therapy (ADT) improved 5-yr overall survival significantly in patients with metastatic hormone-sensitive prostate cancer, with a 30% reduced risk of death versus placebo plus ADT. Survival benefits of enzalutamide were consistent across subgroups, including a notable 36-mo gain in patients with high-volume disease.